Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH
Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH
Pratteln, Switzerland, March 5, 2018 - Santhera Pharmaceuticals (SIX.
Mylan to launch 2 HIV treatments
Mylan to launch 2 HIV treatments
Mylan will soon be bringing its recently approved HIV medications Symfi Lo and Cimduo to market.
Management Board initiates building approval process for EMA premises in Amsterdam
Management Board initiates building approval process for EMA premises in Amsterdam
The European Medicines Agency’s (EMA) Management Board met today in an extraordinary session to further discuss the building approval process for EMA’s future premises in Amsterdam, the Ne...
Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets
Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets
March 5, 2018, San Diego, CA – Vividion Therapeutics, Inc.
IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease
IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease
CARLSBAD, Calif.
Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)
Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)
EXTON, Pa.
BIAL and WhanIn signed an Exclusive Licensing Agreement for Zebinix in South Korea
BIAL and WhanIn signed an Exclusive Licensing Agreement for Zebinix in South Korea
February 27th, 2018 - BIAL and WhanIn Pharm.
Big pharma, big data: why drugmakers want your health records
Big pharma, big data: why drugmakers want your health records
LONDON (Reuters) - Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how me...
FDA approves Sorrento's non-opioid painkiller patch, shares jump
FDA approves Sorrento's non-opioid painkiller patch, shares jump
(Reuters) - Sorrento Therapeutics Inc said on Wednesday the U.
Pfizer could face £502M bill if it comes up short in U.K. patent appeal for Lyrica
Pfizer could face £502M bill if it comes up short in U.K. patent appeal for Lyrica
The U.
Party drug ketamine could prevent depression and PTSD in women, first study in female rats suggests
Party drug ketamine could prevent depression and PTSD in women, first study in female rats suggests
Ketamine could help treat stressed-related disorders, such depression and PTSD, in women, new research claims.
Today is Rare Disease Day 2018!
Today is Rare Disease Day 2018!
With events happening in over 80 countries and regions across the world, together we can raise awareness to help further the rare disease cause.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand